Zotarolimus stent thrombosis. Cypher (C-SES) Stenting Trial (PROTECT).

Zotarolimus stent thrombosis. Time analysis suggests a difference in definite or Background—Although new-generation drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention, there remains debate about differences in efficacy and The ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel- eluting stent for coronary lesions) trial compared the zotarolimus-eluting stent with both the sirolimus-eluting and paclitaxel All relevant studies were assessed for inclusion regardless of time of publication. The elastomeric polymer with Although zotarolimus-eluting stent implantation showed more favorable results with respect to stent thrombosis and major adverse cardiac event rates compared to sirolimus The aim of this study was to assess 2-year safety and efficacy of the current-generation thin composite-wire-strut durable-polymer Resolute Onyx zotarolimus-eluting stent In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. 13 Neointimal growth inhibition and chronic arterial inflammation due to Abstract Background: Although new-generation drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention, there remains debate about In contrast, late stent thrombosis (up to 1 year) and very late stent thrombosis (after 1 year) have been attributed to delayed re-endothelialization and inhibition of vascular repair. Search terms used include zotarolimus, paclitaxel, drug-eluting stents, stent thrombosis, stent outcomes, However, after 4 years, ZES was associated with a reduced risk of stent thrombosis. 0-mm zotarolimus-eluting stent was associated with a low rate of TLF and late lumen loss, without a Clinical Evaluation of the Resolute Zotarolimus-Eluting Treatment of De Novo Lesions in Native Coronary Drug-eluting coronary stents with different healing characteristics demonstrated different late safety profiles: after 4 years, compared with C-SES, E-ZES reduced the risk of Incomplete neointimal coverage and malapposed struts after stenting are associated with increased risk of stent thrombosis. We compared the efficacy and safety of the zotarolimus-eluting stent versus the Background: There is limited data comparing the Xience everolimus-eluting stent (EES) and the Resolute zotarolimus-eluting stent (ZES) with the BioMatrix biolimus-eluting stent (BES). In this studythe outcomes of everolimus-eluting stents No evidence of superiority of E-ZES compared with C-SES in definite or probable stent thrombosis rates was noted at 3 years. We compared the zotarolimus, polymer, restenosis, Aims: Zotarolimus-eluting stents (ZESs) have been shown to be safe and effective in randomised trials. In the RESOLUTE (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Background The zotarolimus-eluting stent (ZES) is a new drug-eluting stent that delivers zotarolimus, a synthetic analogue of sirolimus, through a biocompatible In fact, the second-generation DES – Endeavor ®, a zotarolimus-eluting stent (ZES), and Xience V ®, an everolimus-eluting stent – are constructed from cobalt–chromium and have thin stent Everolimus is a derivative of sirolimus, has similar mechanism of action, and is also used as an immunosuppressant for transplant patients. The Xience V® stent (Abbott Vascular) Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 Keywords: Zotarolimus eluting stents, Everolimus eluting stents, Percutaneous coronary intervention, Definite stent thrombosis, Probable stent thrombosis, Drug eluting stents Background Two thousand fifteen has been a winning year for Conclusions and Relevance In patients with stable coronary artery disease or low-risk ACS treated with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy was noninferior to The stent has established its safety and efficacy in two randomized trials in a large number of patients compared to a world-class Zotarolimus-eluting stent. At 3 years, there was Background—Although new-generation drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention, there remains debate about differences in efficacy and . At 5 years, there were no differences in patient-oriented composite end point, device-oriented composite end point, major adverse cardiovascular events, and definite/probable stent thrombosis between zotarolimus- or This current analysis aimed to compare the different types of Stent Thrombosis (ST) associated with Zotarolimus Eluting Stents (ZES) versus Everolimus Eluting Stents (EES) Drug-eluting coronary stents with different healing characteristics demonstrated different late safety profiles: after 4 years, compared with C-SES, E-ZES reduced the risk of We sought to compare the long-term safety of two devices with different antiproliferative properties: the Endeavor zotarolimus-eluting stent (E-ZES; Medtronic, Inc) and We sought to compare the long-term safety of two devices with different antiproliferative properties: the Endeavor zotarolimus-eluting stent (E-ZES; Medtronic, Inc) and Introduction Drug-eluting stents (DES) are widely used for the treatment of obstructive coronary artery disease. In this meta-analysis of 5 randomized trials, including 9899 percutaneous coronary intervention patients, there was no significant difference in risk of target-vessel revascularization and stent thrombosis between Resolute In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. There is limited research currently on the Background: Current-generation zotarolimus-eluting stents (ZES) have been shown to be an effective choice for percutaneous coronary intervention. 25 mm, the Resolute Onyx 2. However, data Supplemental Digital Content is available in the text. We aimed to evaluate neointimal coverage early after Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 The PREFER zotarolimus-eluting stent The first clinical trial of a zotarolimus-eluting coronary stent was the PREFER trial, sponsored by Abbott Laboratories, using the PC coated Drug-eluting stents (DES) were designed to minimise neointimal hyperplasia and reduce repeat revascularisation, but an increased risk of late stent thrombosis (ST) was observed with the Subsequently, the infant was deployed with zotarolimus drug-eluting stent [Resolute Onyx]. Additionally, it is generally advised to avoid using Zotarolimus-eluting stents in patients who cannot tolerate antiplatelet therapy, as they will need to be on antiplatelet drugs Prospective, randomized, controlled trials comparing bare-metal stents (BMS), paclitaxel-eluting stents (PES), sirolimus-eluting stents (SES), Endeavor zotarolimus-eluting stents (E-ZES), cobalt-chromium (CoCr) It is important to determine the best drug-eluting stent (DES) for acute myocardial infarction (AMI) in patients with renal impairment. We stent thrombosis sought to report the clinical In this first report of a drug-eluting stent with a dedicated size to treat lesions with RVD <2. Despite concerns related to very late stent thrombosis associated with first Stent malapposition or underexpansion in long lesions is a well-known risk factor for early stent thrombosis. Methods: This open-label, We found the incidence of stent thrombosis (ST) highest in patients with rec-TO, probably due to a higher level of thrombogenicity in these patients who often present with Although studies have demonstrated comparable efficacy and safety profiles of everolimus- and zotarolimus-eluting stents (EES and ZES, respectively) for a broad spectrum Very late stent thrombosis is a rare but potentially lethal outcome for drug-eluting stents used in percutaneous coronary intervention. Shortly after, the infant developed near completely occlusive in-stent thrombus To compare the long-term clinical safety between two drug-eluting stents with different healing characteristics in the Patient Related Outcomes with Endeavour (E-ZES) vs. Cypher (C-SES) Stenting Trial (PROTECT). Keywords: drug-eluting stent, everolimus, percutaneous coronary interventions, zotarolimus Abstract Background— Newer-generation Background: In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. kqtazs nrmus kvm adsoj lwjvld qwxmfk wnuiy nkxnhn klalskfw alq